source
- Sanofi halts Phase 3 trial of riliprubart in rare neurological disorderSanofi announced it is ending the Phase 3 study of its antibody drug riliprubart aimed at treating a rare neurological disease. The decision follows a recommendation from an independent data monit…
- Republican pushback on methadone and buprenorphine raises concerns among addiction expertsRecent guidance from the Trump administration has revived a debate over the use of methadone and buprenorphine for opioid addiction treatment, prompting renewed scrutiny of federal policy. Addicti…